{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:25:22Z","timestamp":1788877522724,"version":"build-2803163510"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND:<\/jats:title>\n            <jats:p>Adjuvant therapy for most sentinel-node\u2013positive (stage IIIA) melanoma may have limited clinical benefit for older patients given the competing risk of non-cancer death. The objective of this study is to model the clinical effect and cost of adjuvant therapy in stage IIIA melanoma across age groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>STUDY DESIGN:<\/jats:title>\n            <jats:p>A Markov decision analysis model simulated the overall survival of patients with resected stage IIIA melanoma treated with adjuvant therapy vs observation. In the adjuvant approach, patients are modeled to receive adjuvant pembrolizumab (BRAF wild type) or dabrafenib\/trametinib (BRAF mutant). In the observation approach, treatment is deferred until recurrence. Transition variables were derived from landmark randomized trials in adjuvant and salvage therapy. The model was analyzed for age groups spanning 40 to 89 years. The primary outcome was the number needed to treat (NNT) to prevent one melanoma-related death at 10 years. Cost per mortality avoided was estimated using Medicare reimbursement rates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Projections for NNT among BRAF wild type patients increased by age from 14.71 (age 40 to 44) to 142.86 (age 85 to 89), with patients in cohorts over the age of 75 having an NNT over 25. The cost per mortality avoided ranged from $2.75 million (M) (age 40 to 44) to $27.57M (age 85 to 89). Corresponding values for BRAF mutant patients were as follows: NNT 18.18 to 333.33; cost per mortality avoided ranged from $2.75M to $54.70M.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Universal adjuvant therapy for stage IIIA melanoma is costly and provides limited clinical benefit in patients older than 75 years.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/xcs.0000000000000088","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T01:10:40Z","timestamp":1649121040000},"page":"521-528","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Treat Now or Treat Later: Comparative Effectiveness of Adjuvant Therapy in Resected Stage IIIA Melanoma"],"prefix":"10.1097","volume":"234","author":[{"given":"Emily Z","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Surgery\/Division of General and Oncologic Surgery (Ma, Terhune, Zafari, Blackburn, Olson, Hu), University of Maryland Medical Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia H","family":"Terhune","sequence":"additional","affiliation":[{"name":"Department of Surgery\/Division of General and Oncologic Surgery (Ma, Terhune, Zafari, Blackburn, Olson, Hu), University of Maryland Medical Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafar","family":"Zafari","sequence":"additional","affiliation":[{"name":"Department of Surgery\/Division of General and Oncologic Surgery (Ma, Terhune, Zafari, Blackburn, Olson, Hu), University of Maryland Medical Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle W","family":"Blackburn","sequence":"additional","affiliation":[{"name":"Department of Surgery\/Division of General and Oncologic Surgery (Ma, Terhune, Zafari, Blackburn, Olson, Hu), University of Maryland Medical Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Olson","sequence":"additional","affiliation":[{"name":"Department of Surgery\/Division of General and Oncologic Surgery (Ma, Terhune, Zafari, Blackburn, Olson, Hu), University of Maryland Medical Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Daniel","family":"Mullins","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Health Services Research (Mullins), University of Maryland Medical Center, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Surgery\/Division of General and Oncologic Surgery (Ma, Terhune, Zafari, Blackburn, Olson, Hu), University of Maryland Medical Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"R2-20250821","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/cam4.1152","article-title":"Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992-2011.","volume":"6","author":"Enninga","year":"2017","journal-title":"Cancer Med"},{"key":"R3-20250821","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R5-20250821","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma.","volume":"383","author":"Dummer","year":"2020","journal-title":"N Engl J Med"},{"key":"R6-20250821","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma.","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"R7-20250821","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"R8-20250821","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma.","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"R9-20250821","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/13696998.2019.1609485","article-title":"Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.","volume":"22","author":"Bensimon","year":"2019","journal-title":"J Med Econ"},{"key":"R11-20250821","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"key":"R12-20250821","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma.","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"R13-20250821","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"R14-20250821","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma.","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"R15-20250821","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma.","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"R16-20250821","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.18.02306","article-title":"Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node.","volume":"37","author":"Leiter","year":"2019","journal-title":"J Clin Oncol"},{"key":"R17-20250821","first-page":"1","article-title":"United States Life Tables, 2017.","volume":"68","author":"Arias","year":"2019","journal-title":"Nat Vital Stat Rep"},{"key":"R19-20250821","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40487-021-00142-8","article-title":"Cost-effectiveness of pembrolizumab for the adjuvant treatment of melanoma patients with lymph node involvement who have undergone complete resection in Argentina.","volume":"9","author":"Wurcel","year":"2021","journal-title":"Oncol Ther"},{"key":"R20-20250821","first-page":"184","article-title":"Cost-effectiveness of pembrolizumab versus ipilimumab in ipilimumab-na\u00efve patients with advanced melanoma in the United States.","volume":"23","author":"Wang","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"R21-20250821","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1080\/13696998.2019.1635487","article-title":"Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E\/K mutation-positive melanoma from a US healthcare payer perspective.","volume":"22","author":"Gerbasi","year":"2019","journal-title":"J Med Econ"},{"key":"R22-20250821","doi-asserted-by":"crossref","first-page":"S457","DOI":"10.1016\/j.jval.2019.09.305","article-title":"PCN108 nivolumab-adjuvant therapy for resected stage III-IV melanoma: a cost-effectiveness analysis for SPAIN.","volume":"22","author":"Presa","year":"2019","journal-title":"Value in Health"},{"key":"R23-20250821","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2019.06.011","article-title":"Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma.","volume":"119","author":"Kanaki","year":"2019","journal-title":"Eur J Cancer"},{"key":"R24-20250821","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12885-018-4016-3","article-title":"Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.","volume":"18","author":"Zager","year":"2018","journal-title":"BMC Cancer"},{"key":"R25-20250821","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jamcollsurg.2020.08.750","article-title":"Cost-benefit implication of gene expression profiling and adjuvant therapy in stage IIIA melanoma.","volume":"231","author":"Hu","year":"2020","journal-title":"J Am Coll Surg"},{"key":"R26-20250821","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2020.1731","article-title":"Performance of gene expression profile tests for prognosis in patients with localized cutaneous melanoma: a systematic review and meta-analysis.","volume":"156","author":"Marchetti","year":"2020","journal-title":"JAMA Dermatol"},{"key":"R27-20250821","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.18632\/oncotarget.2907","article-title":"Stage-specific prognostic biomarkers in melanoma.","volume":"6","author":"Cheng","year":"2015","journal-title":"Oncotarget"},{"key":"R28-20250821","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/annonc\/mdz075","article-title":"Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.","volume":"30","author":"Lee","year":"2019","journal-title":"Ann Oncol"},{"key":"R29-20250821","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2019.07.004","article-title":"Melanoma-specific survival in patients with positive sentinel lymph nodes: relevance of sentinel tumor burden.","volume":"123","author":"Satzger","year":"2019","journal-title":"Eur J Cancer"},{"key":"R30-20250821","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Journal of the American College of Surgeons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/XCS.0000000000000088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T20:07:57Z","timestamp":1755806877000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/XCS.0000000000000088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/xcs.0000000000000088","relation":{},"ISSN":["1072-7515"],"issn-type":[{"value":"1072-7515","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,28]]}}}